News Sentiment

EIKN sentiment intelligence

Eikon Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 73 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 9.77 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 65

directly relevant articles

Source quality 8

high-authority source matches

Trend context Trend inactive

-7.7% over one week, +1.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Eikon Therapeutics: Behind The Rough Debut (NASDAQ:EIKN)

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -7.7% Price reacting lower
Trend fit Trend inactive 1.7% over four weeks
Fair value -13.9% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 47
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 65
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Market source 9
www.marketscreener.com 5
GlobeNewswire 5
Stock Titan 4
Seeking Alpha 3
MarketBeat 3
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 45
Earnings 18
Analyst action 6
Guidance 3
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 73
Stock Titan Direct company coverage

Seven Eikon abstracts include lung and prostate cancer studies at ESMO

Eikon Therapeutics (Nasdaq: EIKN) announced that seven abstracts detailing progress across its oncology pipeline have been accepted for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress. These abstracts include updated Phase 2 data for EIK1001 in non-s

Tone
Positive 71/100
Event
Market update
Published
20 Jul 2026 12:10
Source
Stock Titan
Yahoo! Finance Canada Direct company coverage

Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress

Eikon Therapeutics announced that seven abstracts covering progress across its lead oncology programs have been accepted for presentation at the 2026 European Society of Medical Oncology (ESMO) Congress. These presentations will include updated data from ongoing trials for EIK100

Tone
Positive 71/100
Event
Market update
Published
20 Jul 2026 12:10
Source
Yahoo! Finance Canada
Insider Monkey Direct company coverage

Is Eikon Therapeutics, Inc. (EIKN) Stock a Biotech Growth Opportunity Despite Limited Q1 Updates?

Eikon Therapeutics, Inc. (EIKN) is highlighted as a promising biopharmaceutical stock, despite limited Q1 updates, following BofA Securities lowering its price target while maintaining a Buy rating. The company recently achieved a significant milestone with its upcoming inclusion

Tone
Positive 66/100
Event
Analyst action
Published
02 Jul 2026 19:41
Source
Insider Monkey
Moomoo Direct company coverage

Eikon Therapeutics to Join Russell 3000 Index Following Annual Reconstitution

Eikon Therapeutics, Inc. (EIKN), a biotechnology company, is set to join the Russell 3000 Index as part of the 2026 annual reconstitution. This inclusion means Eikon Therapeutics will be automatically added to the appropriate growth and value indexes, as well as the Russell 1000

Tone
Positive 74/100
Event
Market update
Published
30 Jun 2026 01:40
Source
Moomoo
TradingView Direct company coverage

Enterprise value to revenue forward of Eikon Therapeutics, Inc. – NASDAQ:EIKN

This page provides financial data on Eikon Therapeutics, Inc. (NASDAQ: EIKN), specifically focusing on its enterprise value to revenue forward metric. The content highlights a specific financial period and value, along with information about data providers and copyright.

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 01:40
Source
TradingView
www.marketscreener.com Direct company coverage

Eikon Therapeutics, Inc.(NasdaqGS:EIKN) added to Russell Microcap Growth Benchmark Index

Eikon Therapeutics, Inc. (NasdaqGS:EIKN) has been added to the Russell Microcap Growth Benchmark Index. This inclusion is one of several recent additions of Eikon Therapeutics to various Russell indices, including the Russell 2000 Index, Russell Microcap Value Benchmark Index, an

Tone
Positive 70/100
Event
Market update
Published
29 Jun 2026 23:09
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 2000 Index

Eikon Therapeutics, Inc. (NasdaqGS: EIKN) has been added to the Russell 2000 Index, as well as several other Russell indices including the Microcap Value Benchmark, 2000 Value Benchmark, Microcap Growth Benchmark, 2000 Growth Benchmark, 3000E Growth Benchmark, and Microcap Index.

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 21:56
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 2000 Growth Benchmark

Eikon Therapeutics, Inc. (NasdaqGS:EIKN) has been added to the Russell 2000 Growth Benchmark as of June 29, 2026. This inclusion is part of a series of additions for Eikon Therapeutics to various Russell indices, including the Russell 2000 Index, Russell Microcap Value Benchmark,

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 11:40
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 3000E Growth Benchmark

Eikon Therapeutics, Inc. (NasdaqGS:EIKN) has been added to the Russell 3000E Growth Benchmark. This news comes shortly after the company was also added to the Russell Microcap Index and the S&P Global BMI Index, indicating increased recognition within key market indices. The comp

Tone
Positive 75/100
Event
Market update
Published
29 Jun 2026 09:39
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 2000 Value Benchmark

Eikon Therapeutics, Inc. (NasdaqGS: EIKN) has been added to the Russell 2000 Value Benchmark index. This inclusion is part of several recent additions to various Russell indices, including the Russell 2000 Index, Russell Microcap Value Benchmark Index, and Russell Microcap Growth

Tone
Positive 72/100
Event
Market update
Published
28 Jun 2026 15:10
Source
www.marketscreener.com
TradingView Direct company coverage

Enterprise value to EBIT forward of Eikon Therapeutics, Inc. – BOATS:EIKN

The article discusses the Enterprise Value to EBIT forward metric for Eikon Therapeutics, Inc. (EIKN). It provides a brief overview of the company's financial data as listed on TradingView, indicating that the market is currently closed with no trades. The content primarily focus

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 23:09
Source
TradingView
TradingView Direct company coverage

Price to book forward of Eikon Therapeutics, Inc. – NASDAQ:EIKN

This article focuses on the "Price to book forward" metric for Eikon Therapeutics, Inc., traded on the Nasdaq Stock Market under the ticker EIKN. It appears to be an announcement or a data point provided by TradingView, indicating a specific financial ratio for the company.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 23:09
Source
TradingView
Finviz Direct company coverage

EIKN - Eikon Therapeutics Inc Short Interest

This article provides comprehensive financial data for Eikon Therapeutics Inc. (EIKN), focusing on its short interest. It details key financial metrics, stock performance, insider and institutional ownership, analyst recommendations, and various valuation ratios. The data highlig

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 12:10
Source
Finviz
GlobeNewswire Direct company coverage

Eikon Therapeutics to Join the Russell 3000® Index

Eikon Therapeutics, a late-stage clinical biopharmaceutical company, announced its inclusion in the broad-market Russell 3000® Index, effective after the US market closes on June 26, 2026. This addition highlights Eikon's progress as a publicly traded entity and its growing prese

Tone
Positive 73/100
Event
Market update
Published
26 Jun 2026 10:09
Source
GlobeNewswire
TradingView Direct company coverage

Enterprise value to EBITDA forward of Eikon Therapeutics, Inc. – NASDAQ:EIKN

This article provides access to the enterprise value to EBITDA forward data for Eikon Therapeutics, Inc. (NASDAQ: EIKN) on TradingView. It appears to be a financial data page rather than a traditional article. The page is a directory for financial metrics and general company info

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 10:09
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Eikon Therapeutics, Inc. – NASDAQ:EIKN

This article provides the "Price to sales forward" value for Eikon Therapeutics, Inc. (NASDAQ: EIKN). It is a finance-related piece from TradingView, focusing on the company's financial metrics. The specific value for the forward price-to-sales ratio is presented as part of the c

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 03:41
Source
TradingView
TradingView Direct company coverage

Eikon Therapeutics, Inc. Actuals & Estimates (NASDAQ:EIKN)

This article provides actuals and estimates for Eikon Therapeutics, Inc. (NASDAQ:EIKN), detailing its financial performance, stock price dynamics, and analyst forecasts. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 02:41
Source
TradingView
TradingView Direct company coverage

Price to book forward of Eikon Therapeutics, Inc. – BOATS:EIKN

This article provides the "Price to book forward" financial metric for Eikon Therapeutics, Inc. (EIKN), listed on the Blue Ocean Alternative Trade System (BOATS). It presents the period, value, change, and percentage change. The content appears to be a snapshot from a financial d

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 00:41
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Eikon Therapeutics, Inc. – BOATS:EIKN

This article provides financial information for Eikon Therapeutics, Inc. (EIKN) on the Blue Ocean Alternative Trade System (BOATS), specifically focusing on its forward price-to-earnings ratio. It indicates that the market is currently closed with no trades. The content is primar

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 23:09
Source
TradingView
Investing.com Direct company coverage

Eikon Therapeutics to join Russell 3000 Index on Friday

Eikon Therapeutics (NASDAQ:EIKN) will be added to the Russell 3000 Index after the U.S. market closes on Friday, following the annual reconstitution of Russell U.S. Indexes. The biopharmaceutical company is currently trading at $9.85 with a market capitalization of $521 million,

Tone
Positive 66/100
Event
Market update
Published
25 Jun 2026 21:41
Source
Investing.com
Investing.com Canada Direct company coverage

Eikon Therapeutics to join Russell 3000 Index on Friday By Investing.com

Eikon Therapeutics, Inc. (NASDAQ:EIKN) will be added to the Russell 3000 Index after the U.S. market closes on Friday, following the annual reconstitution of the Russell U.S. Indexes. The company currently trades at $9.85 with a market capitalization of $521 million, though share

Tone
Positive 66/100
Event
Market update
Published
25 Jun 2026 20:25
Source
Investing.com Canada
TradingView Direct company coverage

Price to earnings forward of Eikon Therapeutics, Inc. – NASDAQ:EIKN

This article provides a financial snapshot of Eikon Therapeutics, Inc. (NASDAQ: EIKN), specifically focusing on its forward price-to-earnings ratio. It indicates that the market is currently closed for the stock, with no trades recorded. The content seems to be a financial data p

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 15:40
Source
TradingView
TradingView Direct company coverage

EIKN Forecast — Price Target — Prediction for 2027

This article provides a detailed forecast and price target for Eikon Therapeutics, Inc. (EIKN) stock, including analyst ratings and future predictions. It covers current market performance, historical highs and lows, volatility, market capitalization, and upcoming earnings report

Tone
Neutral 50/100
Event
Analyst action
Published
24 Jun 2026 02:09
Source
TradingView